MedTrace Logo

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

NCT00730288 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-02-27

No results posted yet for this study

Summary

To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine

Primary Objectives:

* To describe the safety of one injection of ChimeriVax™ dengue tetravalent vaccine.
* To describe the immune response against dengue before and after one injection of ChimeriVax™ dengue tetravalent vaccine

Conditions

  • Dengue
  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Dengue Virus

Interventions

BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5 mL, Subcutaneous, 1 dose

BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5 mL, Subcutaneous, 1 dose

BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5mL, Subcutaneous, 1 dose

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Sanofi Pasteur Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-08-31
Completion
2008-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730288 on ClinicalTrials.gov